Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 76

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A)

  • The report reviews Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Overview 7
Therapeutics Development 8
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Stage of Development 8
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Therapy Area 9
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Indication 10
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Companies 13
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Companies Involved in Therapeutics Development 21
AbbVie Inc 21
Abeome Corporation 22
Affibody AB 23
Cell Medica Limited 24
Eli Lilly and Company 25
Johnson & Johnson 26
Merck KGaA 27
Novartis AG 28
Orega Biotech SAS 29
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Drug Profiles 30
ABT-122 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ABY-035 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CNTO-6785 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
DLX-2882 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
DLX-2907 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DLX-2909 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ixekizumab - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
M-1095 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibody to Inhibit IL-17A for Psoriasis and Inflammation - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
OREG-203 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
secukinumab - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Dormant Projects 60
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Discontinued Products 61
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Featured News & Press Releases 62
Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis 62
Jun 21, 2016: Health Canada approval of Taltz (ixekizumab) Brings Targeted Therapy to Canadians Living with Moderate-to-Severe Plaque Psoriasis 62
Jun 09, 2016: New drug clears psoriasis in clinical trials 64
Jun 08, 2016: Studies Demonstrate Lilly's Taltz (Ixekizumab) Maintained Or Achieved High Levels Of Skin Clearance For Patients With Moderate-To-Severe Plaque Psoriasis Through 60 Weeks: Results Published In The New England Journal Of Medicine 65
Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 66
Jun 07, 2016: Eli Lilly and Company Announces Data on Ixekizumab At Annual European Congress Of Rheumatology 67
Jun 07, 2016: Tampa Dermatologist Launches Clinical Trial for Psoriatic Arthritis Patients 68
Jun 02, 2016: AbbVie Announces Presentation on ABT-122 at the Annual European Congress of Rheumatology 68
May 04, 2016: Affibody Announces Initial Results from a Phase I Study of ABY-035 69
May 02, 2016: Lilly's Taltz (Ixekizumab) Now Available In The U.S. For The Treatment Of Moderate-To-Severe Plaque Psoriasis 69
Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada 71
Apr 26, 2016: Lilly announces European Commission approval for plaque psoriasis drug 71
Apr 23, 2016: OptiMed Specialty Pharmacy to Distribute Cosentyx 72
Apr 05, 2016: Diplomat Announces TALTZ Availability for the Treatment of Plaque Psoriasis 72
Mar 22, 2016: Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Moderate-To-Severe Plaque Psoriasis 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by AbbVie Inc, H2 2016 21
Pipeline by Abeome Corporation, H2 2016 22
Pipeline by Affibody AB, H2 2016 23
Pipeline by Cell Medica Limited, H2 2016 24
Pipeline by Eli Lilly and Company, H2 2016 25
Pipeline by Johnson & Johnson, H2 2016 26
Pipeline by Merck KGaA, H2 2016 27
Pipeline by Novartis AG, H2 2016 28
Pipeline by Orega Biotech SAS, H2 2016 29
Dormant Projects, H2 2016 60
Discontinued Products, H2 2016 61

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Actions, H2 2016 16
Number of Products by Routes of Administration, H2 2016 17
Number of Products by Stage and Routes of Administration, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 19
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • United States Digital PCR (DPCR) And QPCR Market Report 2017
    Published: 26-Apr-2017        Price: US 3800 Onwards        Pages: 107
    In this report, the United States Digital PCR (DPCR) And QPCR market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and gro......
  • Global Gene Synthesis Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 25-Apr-2017        Price: US 3480 Onwards        Pages: 117
    Gene synthesis refers to chemically synthesizing a strand of DNA base-by-base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for creation of a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built. ......
  • High-Resolution Melting Analysis Market by Product (Supermix Reagent, RT PCR Instrument, Software), Application (SNP Genotyping, Mutation Discovery, Epigenetics), Enduser (Research Laboratories, Hospital, Diagnostic Center) - Global Forecast to 2021
    Published: 25-Apr-2017        Price: US 5650 Onwards        Pages: 143
    The global high-resolution melting analysis market is expected to reach USD 302.1 million by 2021 from USD 259.4 million in 2016, at a CAGR of 3.1% during the forecast period of 2016 to 2021.On the basis of product & service, the high-resolution melting analysis market is segmented into instruments, reagents & consumables, and software & services. The reagents and consumables segment dominated the market in 2016 and is expected to continue its dominance during the forecast period.......
  • North America Gene Synthesis Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 25-Apr-2017        Price: US 4480 Onwards        Pages: 117
    Gene synthesis refers to chemically synthesizing a strand of DNA base-by-base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for creation of a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built. ......
  • 2017-2022 United States Human Micobiome Market Report (Status and Outlook)
    Published: 20-Apr-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Human Micobiome market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In United States market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Vedanta - Seres Therapeuti......
  • Global Jinggangmycin Market Professional Survey Report 2017
    Published: 20-Apr-2017        Price: US 3500 Onwards        Pages: 100
    This report studies Jinggangmycin in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Zhejiang Qianjiang Biochemical - Shanghai Tongrui Biotech - Jiangxi Xinruifen......
  • 2017-2022 Global Top Countries Human Micobiome Market Report
    Published: 20-Apr-2017        Price: US 4960 Onwards        Pages: 126
    "This report will be delivered in 2-3 business days after the order is placed." This report studies Human Micobiome in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and Africa, focuses on the top Manufacturers in each country, covering - Vedanta - Seres Therapeutics - Second Genome - Rebiotix - ActoGen......
  • 2017-2022 Japan Human Micobiome Market Report (Status and Outlook)
    Published: 20-Apr-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Human Micobiome market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Vedanta - Seres Therapeutics - Seco......
  • 2017-2022 UK Human Micobiome Market Report (Status and Outlook)
    Published: 20-Apr-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Human Micobiome market size will be XX million (USD) in 2022 in UK, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In UK market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Vedanta - Seres Therapeutics - Second Gen......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs